GlassScriptPhysician profile
Jennifer Pate
NPI 1972048304
$5,670.95
in general payments reported to CMS, 2019-2025
31 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,486 · 2022: $1,550 · 2023: $905 · 2024: $1,312 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,817 · Travel and Lodging: $818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,816.77 |
| Travel and Lodging | $818.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,142.14 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Intuitive Surgical, INC. | $885.78 | 2023-2024 | Da Vinci Surgical System |
| Atricure, INC. | $417.41 | 2021-2024 | |
| Jazz Pharmaceuticals INC. | $370.36 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $350.33 | 2021-2025 | Ofev |
| Mallinckrodt Hospital Products INC. | $324.53 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $308.00 | 2021-2023 | Breztri |
| Genzyme Corporation | $282.29 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $265.57 | 2022-2024 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $252.85 | 2021-2023 | Uptravi |
| Abbvie INC. | $233.33 | 2021-2022 | |
| Pfizer INC. | $139.86 | 2023-2025 | |
| United Therapeutics Corporation | $111.70 | 2021-2022 | |
| Pulmonx Corporation | $72.04 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Baxter Healthcare | $64.02 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $54.16 | 2022 | |
| Merck Sharp & Dohme LLC | $51.79 | 2021-2023 | Zerbaxa, Recarbrio |
| E.R. Squibb & Sons, L.L.C. | $43.32 | 2021 | |
| Mylan Specialty L.P. | $42.71 | 2022 | |
| Davol INC. | $36.78 | 2023 | Arista Ah Flexitip |
| Becton, Dickinson and Company | $29.34 | 2023 | Phasix Mesh |
| Inari Medical, INC. | $25.49 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| La Jolla Pharmaceutical Company | $22.05 | 2025 | Giapreza |
| Verona Pharma, INC. | $21.48 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $20.38 | 2022 | |
| Grifols USA, LLC | $19.68 | 2022 | |
| Advanced Respiratory, INC | $18.24 | 2021 | |
| Novocure INC. | $17.50 | 2025 | Optune Lua (Novottf-200t) |
| Philips North America LLC | $17.21 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.59 | 2025 | Glassia |
| Mayne Pharma Commercial LLC | $15.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Pate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.